

DAFTAR PUSTAKA

- ACOG, A. C. of O. and G. (2015). Salpingectomy in Ovarian Cancer Prevention. *American College of Obstetricians and Gynecologists*, 125(1), 279–281.
<https://doi.org/10.1001/jama.2023.6979>
- Ali, A. T., Al-Ani, O., & Al-Ani, F. (2023). Epidemiology and risk factors for ovarian cancer. *Przegląd Menopauzalny*, 22(2), 93–104.
<https://doi.org/10.5114/pm.2023.128661>
- Andreou, M., Kyprianidou, M., Cortas, C., Polycarpou, I., Papamichael, D., Kountourakis, P., & Giannakou, K. (2023). Prognostic Factors Influencing Survival in Ovarian Cancer Patients: A 10-Year Retrospective Study. *Cancers*, 15(24), 1–13. <https://doi.org/10.3390/cancers15245710>
- Arora, T., Mullangi, S., & Lekkala, M. R. (2023). Ovarian cancer. *StatPearls Publishing*, June, 433–440.
[https://www.sciencedirect.com/science/article/abs/pii/S1040842806000643?](https://www.sciencedirect.com/science/article/abs/pii/S1040842806000643?via%3Dihub)
via%3Dihub
- Arora, T., Mullangi, S., Vadakekut, E. S., & Lekkala, M. R. (2024). Epithelial ovarian cancer. *StatPearls Publishing*.
- Asem, M., Young, A., Oyama, C., ClaireDeLaZerda, A., Liu, Y., Ravosa, M. J., Gupta, V., Jewell, A., Khabele, D., & Stack, M. S. (2020). Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer. *Scientific Reports*, 10(1), 1–14.
<https://doi.org/10.1038/s41598-020-68639-2>
- Birbrair, A. (2020). Tumor microenvironment. In *Medicina (Lithuania)* (Vol. 56, Issue 1). <https://doi.org/10.3390/medicina56010015>
- Bjersand, K., Blom, K., Poromaa, I. S., Stålberg, K., Lejon, A. M., Bäckman, F., Nyberg, Å., Andersson, C., Larsson, R., & Nygren, P. (2022). Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome. *International Journal of Oncology*, 61(4), 1–9.
<https://doi.org/10.3892/ijo.2022.5418>
- Blanc-Durand, F., Clemence Wei Xian, L., & Tan, D. S. P. (2023). Targeting the

immune microenvironment for ovarian cancer therapy. In *Frontiers in Immunology* (Vol. 14, Issue December, pp. 1–20).

<https://doi.org/10.3389/fimmu.2023.1328651>

Boussios, S., Rassy, E., Moschetta, M., Ghose, A., Adeleke, S., Sanchez, E., Sheriff, M., Chargari, C., & Pavlidis, N. (2022). BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. In *Cancers* (Vol. 14, Issue 16, pp. 1–29). <https://doi.org/10.3390/cancers14163888>

Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (2017). Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma. *TNM Online*, 179–184. <https://doi.org/10.1002/9780471420194.tnmc84>

Brodeur, M. N., Dejean, R., Beauchemin, M. C., Samouëlian, V., Cormier, B., Bacha, O. M., Warkus, T., & Barkati, M. (2021). Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer. *Gynecologic Oncology*, 162(2), 277–283. <https://doi.org/10.1016/j.ygyno.2021.05.023>

Bryant, A., Hiu, S., Kunonga, P. T., Gajjar, K., Craig, D., Vale, L., Winter-Roach, B. A., Elattar, A., & Naik, R. (2022). Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. *Cochrane Database of Systematic Reviews*, 2022(9). <https://doi.org/10.1002/14651858.CD015048.pub2>

Bryk, S., Katuwal, S., Haltia, U.-M., Tapper, J., Tapanainen, J. S., & Pukkala, E. (2021). Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study. *Gynecologic Oncology*, 163(3), 593–597. <https://doi.org/10.1016/j.ygyno.2021.09.013>

Budiana, I. N. G., Angelina, M., & Pemayun, T. G. A. (2019). Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *Journal of the Turkish-German Gynecological Association*, 20(1), 47–54. <https://doi.org/10.4274/jtgga.galenos.2018.2018.0119>

Capellero, S., Erriquez, J., Battistini, C., Porporato, R., Scotto, G., Borella, F., Di Renzo, M. F., Valabrega, G., & Olivero, M. (2022). Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal

Phenotype and Allows Survival and Proliferation of Metastasizing Cells.

International Journal of Molecular Sciences, 23(2).

<https://doi.org/10.3390/ijms23020833>

Chang, L. C., Huang, C. F., Lai, M. S., Shen, L. J., Wu, F. L. L., & Cheng, W. F.

(2018). Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS ONE*, 13(3), 1–11. <https://doi.org/10.1371/journal.pone.0194993>

Chardin, L., & Leary, A. (2021). Immunotherapy in Ovarian Cancer: Thinking

Beyond PD-1/PD-L1. In *Frontiers in Oncology* (Vol. 11, Issue December, pp. 1–10). <https://doi.org/10.3389/fonc.2021.795547>

Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F., Narod, S., & Akbari, M.

(2020). CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel)*. <https://doi.org/10.1201/9781003353034-6>

Chase, D. M., Mahajan, A., Scott, D. A., Hawkins, N., & Kalilani, L. (2023).

Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: A systematic literature review. *International Journal of Gynecological Cancer*, 33(10), 1602–1611. <https://doi.org/10.1136/ijgc-2023-004487>

Chase, D. M., Mahajan, A., Scott, D. A., Hawkins, N., & Kalilani, L. (2024). The

impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis. *BMC Women's Health*, 24(1), 1–11. <https://doi.org/10.1186/s12905-024-02977-5>

Chen, G. M., Kannan, L., Geistlinger, L., Kofia, V., Safikhani, Z., Gendoo, D. M.

A., Parmigiani, G., Birrer, M., Haibe-Kains, B., & Waldron, L. (2018).

Consensus on molecular subtypes of high-grade serous ovarian carcinoma. *Clinical Cancer Research*, 24(20), 5037–5047. <https://doi.org/10.1158/1078-0432.CCR-18-0784>

Cianci, S., Capozzi, V. A., Rosati, A., Rumolo, V., Corrado, G., Uccella, S., Gueli

Alletti, S., Riccò, M., Fagotti, A., Scambia, G., & Cosentino, F. (2022).

Different Surgical Approaches for Early-Stage Ovarian Cancer Staging. A Large Monocentric Experience. *Frontiers in Medicine*, 9(April), 1–9.

<https://doi.org/10.3389/fmed.2022.880681>

- Cohen, J. (2013). Statistical Power Analysis for the Behavioral Sciences. In *Statistical Power Analysis for the Behavioral Sciences*.
<https://doi.org/10.4324/9780203771587>
- Elzakkers, J. C. J., van der Aa, M. A., van Altena, A. M., de Hullu, J. A., & Harmsen, M. G. (2019). Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer. *Gynecologic Oncology*, 155(2), 213–219.
<https://doi.org/10.1016/j.ygyno.2019.08.018>
- Eoh, K. J., Park, J., Kim, H. M., Lee, M., & Kim, Y. T. (2021). Comparison of the prognostic outcome between high-grade ovarian sertoli-leydig cell tumors (SLCTs) and low-grade SLCTs. *Yonsei Medical Journal*, 62(4), 366–369.
<https://doi.org/10.3349/ymj.2021.62.4.366>
- Eslahi, M., Roshandel, G., & Torkian, S. (2022). Trends in the Incidence Rates of Breast and Gynecological Cancers in Asia from 1998-2012: An Ecological Study. *Archives of Iranian Medicine*, 25(2), 112–117.
<https://doi.org/10.34172/aim.2022.18>
- Fahmi, M. N., Pradjatmo, H., Astuti, I., & Nindrea, R. D. (2021). Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis. *Asian Pacific Journal of Cancer Prevention*, 22(2), 315–323. <https://doi.org/10.31557/APJCP.2021.22.2.315>
- Farghaly, S. (2012). *OVARIAN CANCER – BASIC SCIENCE PERSPECTIVE*. BoD–Books on Demand.
- Fleischer, A. C., Alvarez, R. D., & Dubinsky, T. J. (2020). Improved Sonographic Detection of Epithelial Ovarian Cancer: New Concepts and Evolving Technology. *Ultrasound Quarterly*, 36(2), 133–137.
<https://doi.org/10.1097/RUQ.0000000000000502>
- Gaona-Luviano, P., Adriana, L., Medina-Gaona, & Magaña-Pérez, K. (2020). Epidemiology of ovarian cancer. *Chinese Clinical Oncology*, 9(4).
<https://doi.org/10.21037/cco-20-34>
- Guo, J. Z., Xiao, Q., Gao, S., Li, X. Q., Wu, Q. J., & Gong, T. T. (2021). Review of Mendelian Randomization Studies on Ovarian Cancer. *Frontiers in*

- Oncology*, 11(August), 1–18. <https://doi.org/10.3389/fonc.2021.681396>
- Gupta, D., & Lis, C. G. (2009). Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. *Journal of Ovarian Research*, 2(1), 1–20. <https://doi.org/10.1186/1757-2215-2-13>
- Gupta, N., Yadav, M., Gupta, V., Chaudhary, D., & Patne, S. C. U. (2019). Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh. *Journal of Laboratory Physicians*, 11(01), 075–081. https://doi.org/10.4103/jlp.jlp_117_18
- Han, C. L., Meng, G. X., Ding, Z. N., Dong, Z. R., Chen, Z. Q., Hong, J. G., Yan, L. J., Liu, H., Tian, B. W., Yang, L. S., Xue, J. S., & Li, T. (2022). The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. *Frontiers in Immunology*, 13(February), 1–12. <https://doi.org/10.3389/fimmu.2022.827788>
- Hanatani, M., Yoshikawa, N., Yoshida, K., Tamauchi, S., Ikeda, Y., Nishino, K., Niimi, K., Suzuki, S., Kawai, M., Kajiyama, H., & Kikkawa, F. (2020). Impact of age on clinicopathological features and survival of epithelial ovarian neoplasms in reproductive age. *International Journal of Clinical Oncology*, 25(1), 187–194. <https://doi.org/10.1007/s10147-019-01550-7>
- Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020). C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights. *Frontiers in Immunology*, 11(November), 1–17. <https://doi.org/10.3389/fimmu.2020.595835>
- Hayati, A., & Tjahjadi, H. (2023). Profil klinikopatologik metastasis kelenjar getah bening pada karsinoma ovarium di departemen patologi anatomik FKUI/RSCM 2016-2018. *Majalah Patologi Indonesia*, 32(1), 591–597. <https://doi.org/10.55816/mpi.v31i2.569>
- He, D., Zhang, X., Chang, Z., Liu, Z., & Li, B. (2024). Survival time prediction in patients with high-grade serous ovarian cancer based on 18F-FDG PET/CT-derived inter-tumor heterogeneity metrics. *BMC Cancer*, 24(1), 1–13.

<https://doi.org/10.1186/s12885-024-12087-y>

Hirst, J., Crow, J., & Godwin, A. (2018). Ovarian Cancer Genetics: Subtypes and Risk Factors. *Ovarian Cancer - From Pathogenesis to Treatment*, May.

<https://doi.org/10.5772/intechopen.72705>

Höhn, A. K., Brambs, C. E., Hiller, G. G. R., May, D., Schmoeckel, E., & Horn, L. C. (2021). 2020 WHO Classification of Female Genital Tumors.

Geburtshilfe Und Frauenheilkunde, 81(10), 1145–1153.

<https://doi.org/10.1055/a-1545-4279>

Hollis, R. L., Croy, I., Churchman, M., Bartos, C., Rye, T., Gourley, C., & Herrington, C. S. (2022). Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. *British Journal of Cancer*, February.

<https://doi.org/10.1038/s41416-022-01874-8>

Huang, Y., Ming, X., Li, B., & Li, Z. (2020). Histological Characteristics and Early-Stage Diagnosis Are Associated With Better Survival in Young Patients With Epithelial Ovarian Cancer: A Retrospective Analysis Based on Surveillance Epidemiology and End Results Database. *Frontiers in Oncology*, 10(December), 1–10. <https://doi.org/10.3389/fonc.2020.595789>

Ida, T., Fujiwara, H., Kiri, T., Taniguchi, Y., & Kohyama, A. (2019).

Relationship between the precursors of high grade serous ovarian cancer and patient characteristics: Decreased incidence of the p53 signature in pregnant women. *Journal of Gynecologic Oncology*, 30(6), 1–9.

<https://doi.org/10.3802/jgo.2019.30.e96>

Joueidi, Y., Dion, L., Bendifallah, S., Mimoun, C., Bricou, A., Timoh, K. N., Collinet, P., Touboul, C., Ouldamer, L., Azaïs, H., Dabi, Y., Akladios, C., Canlorbe, G., Bolze, P. A., Costaz, H., Mezzadri, M., Gauthier, T., Kridelka, F., Chauvet, P., ... Lavoué, V. (2020). Management and survival of elderly and very elderly patients with ovarian cancer: An age-stratified study of 1123 women from the francogyn group. *Journal of Clinical Medicine*, 9(5).

<https://doi.org/10.3390/jcm9051451>

Kaldawy, A., Segev, Y., Lavie, O., Auslender, R., Sopik, V., & Narod, S. A.

- (2016). Low-grade serous ovarian cancer: A review. *Gynecologic Oncology*, 143(2), 433–438. <https://doi.org/10.1016/j.ygyno.2016.08.320>
- Khalafi-Nezhad, A., Ebrahimi, V., Ahmadpour, F., Momtahan, M., Robati, M., Saraf, Z., Ramzi, M., Jowkar, Z., & Ghaffari, P. (2020). Parity as a prognostic factor in patients with advanced-stage epithelial ovarian cancer. *Cancer Management and Research*, 12, 1447–1456. <https://doi.org/10.2147/CMAR.S237073>
- Khashaba, M., Fawzy, M., Abdel-Aziz, A., Eladawei, G., & Nagib, R. (2022). Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach. *Journal of the Egyptian National Cancer Institute*, 34(1). <https://doi.org/10.1186/s43046-022-00104-9>
- Kim, J., Park, E. Y., Kim, O., Schilder, J. M., Coffey, D. M., Cho, C. H., & Bast, R. C. (2018). Cell origins of high-grade serous ovarian cancer. In *Cancers* (Vol. 10, Issue 11). <https://doi.org/10.3390/cancers10110433>
- Kim, S. J., Rosen, B., Fan, I., Ivanova, A., McLaughlin, J. R., Risch, H., Narod, S. A., & Kotsopoulos, J. (2017). Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. *British Journal of Cancer*, 116(7), 964–971. <https://doi.org/10.1038/bjc.2017.35>
- Kim, S. J., Tworoger, S. S., Rosen, B. P., McLaughlin, J. R., Risch, H. A., Narod, S. A., & Kotsopoulos, J. (2024). Impact of Pre-Diagnostic Risk Factors on Short- and Long-Term Ovarian Cancer Survival Trajectories: A Longitudinal Observational Study. *Cancers*, 16(5). <https://doi.org/10.3390/cancers16050972>
- Köbel, M., & Kang, E. Y. (2022). The Evolution of Ovarian Carcinoma Subclassification. *Cancers*, 14(2), 1–16. <https://doi.org/10.3390/cancers14020416>
- Kolomeyevskaya, N., Eng, K. H., Khan, A. N. H., Grzankowski, K. S., Singel, K. L., Moysich, K., & Segal, B. H. (2015). Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor- α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. *Gynecologic Oncology*, 138(2), 352–357.

<https://doi.org/10.1016/j.ygyno.2015.05.009>

Komura, N., Mabuchi, S., Shimura, K., Kawano, M., Matsumoto, Y., & Kimura, T. (2021). Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients. *Nutrition and Cancer*, 73(8), 1357–1364.

<https://doi.org/10.1080/01635581.2020.1798479>

Kupec, T., Bleilevens, A., Klein, B., Hansen, T., Najjari, L., Wittenborn, J., Stickeler, E., & Maurer, J. (2023). Comparison of Serum and Urine as Sources of miRNA Markers for the Detection of Ovarian Cancer.

Biomedicines, 11(9). <https://doi.org/10.3390/biomedicines11092508>

Kurman, R. J., & Shih, I. M. (2016). The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. *American Journal of Pathology*, 186(4), 733–747. <https://doi.org/10.1016/j.ajpath.2015.11.011>

Kuroki, L., & Guntupalli, S. R. (2020). Treatment of epithelial ovarian cancer. *The BMJ*, 371, 1–20. <https://doi.org/10.1136/bmj.m3773>

Lai, I., Daniel, M. N., Rosen, B. P., May, T., Massey, C., & Feigenberg, T. (2019). Correlation of differential ascites volume with primary cytoreductive surgery outcome, lymph node involvement, and disease recurrence in advanced ovarian cancer. *International Journal of Gynecological Cancer*, 29(5), 922–928. <https://doi.org/10.1136/ijgc-2019-000310>

Li, H., Liu, Y., Wang, Y., Zhao, X., & Qi, X. (2021). Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). In *Oncology Reports* (Vol. 46, Issue 4, pp. 1–27). <https://doi.org/10.3892/or.2021.8174>

Li, J., Jiao, X., Yuan, Z., Qiu, H., & Guo, R. (2017). C-reactive protein and risk of ovarian cancer. *Medicine (United States)*, 96(34), 1–7. <https://doi.org/10.1097/MD.00000000000007822>

Liberto, J. M., Chen, S. Y., Shih, I. M., Wang, T. H., Wang, T. L., & Pisanic, T. R. (2022). Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. In *Cancers* (Vol. 14, Issue 12). <https://doi.org/10.3390/cancers14122885>

- Liposits, G., Skuladottir, H., Ryg, J., Winther, S. B., Möller, S., Hofslí, E., Shah, C. H., Poulsen, L. Ø., Berglund, Å., Qvortrup, C., Osterlund, P., Johansen, J. S., Glimelius, B., Sorbye, H., & Pfeiffer, P. (2022). The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study. *Journal of Clinical Medicine*, 11(19), 1–15.
<https://doi.org/10.3390/jcm11195603>
- Liu, S., Ding, D., Liu, F., Guo, Y., Xie, L., & Han, F. J. (2024). Exploring the causal role of multiple metabolites on ovarian cancer: a two sample Mendelian randomization study. *Journal of Ovarian Research*, 17(1), 1–14.
<https://doi.org/10.1186/s13048-023-01340-w>
- Liu, T., Gao, Y., Li, S., & Xu, S. (2024). Exploration and prognostic analysis of two types of high-risk ovarian cancers: clear cell vs. serous carcinoma: a population-based study. *Journal of Ovarian Research*, 17(1), 1–19.
<https://doi.org/10.1186/s13048-024-01435-y>
- Luo, X., Xu, J., Yu, J., & Yi, P. (2021). Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer. *Frontiers in Immunology*, 12(June), 1–16. <https://doi.org/10.3389/fimmu.2021.692360>
- Maenhoudt, N., Defraye, C., Boretto, M., Jan, Z., Heremans, R., Boeckx, B., Hermans, F., Arijs, I., Cox, B., Van Nieuwenhuysen, E., Vergote, I., Van Rompuy, A. S., Lambrechts, D., Timmerman, D., & Vankelecom, H. (2020). Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. *Stem Cell Reports*, 14(4), 717–729.
<https://doi.org/10.1016/j.stemcr.2020.03.004>
- Manning-Geist, B., Gordhandas, S., Liu, Y. L., Zhou, Q., Iasonos, A., Da Cruz Paula, A., Mandelker, D., Roche, K. L., Zivanovic, O., Maio, A., Kemel, Y., Chi, D. S., O’Cearbhaill, R. E., Aghajanian, C., Weigelt, B., Chui, M. H., & Grisham, R. N. (2022). MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. *Clinical Cancer Research*, 28(20), 4456–4465. <https://doi.org/10.1158/1078->

0432.CCR-21-4183

Matsuo, K., Machida, H., Mandelbaum, R. S., Konishi, I., & Mikami, M. (2019).

Validation of the 2018 FIGO cervical cancer staging system. *Gynecologic Oncology*, 152(1), 87–93. <https://doi.org/10.1016/j.ygyno.2018.10.026>

Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S., & Sehouli, J. (2015). Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Geburtshilfe Und Frauenheilkunde*, 75(10), 1021–1027. <https://doi.org/10.1055/s-0035-1558079>

Métairie, M., Benoit, L., Koual, M., Bentivegna, E., Wohrer, H., Bolze, P. A., Kerbage, Y., Raimond, E., Akladios, C., Carcopino, X., Canlorbe, G., Uzan, J., Lavoué, V., Mimoun, C., Huchon, C., Koskas, M., Costaz, H., Margueritte, F., Dabi, Y., ... Azaïs, H. (2023). A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer. *Cancers*, 15(3), 1–12. <https://doi.org/10.3390/cancers15030706>

Mitra, A., Yoshida-Court, K., Solley, T. N., Mikkelsen, M., Yeung, C. L. A., Nick, A., Lu, K., & Klopp, A. H. (2021). Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells. *Scientific Reports*, 11(1), 1–11. <https://doi.org/10.1038/s41598-021-88163-1>

Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: Epidemiology and risk factors. In *International Journal of Women's Health* (Vol. 11, pp. 287–299). <https://doi.org/10.2147/IJWH.S197604>

Murakami, R., Matsumura, N., Michimae, H., Tanabe, H., Yunokawa, M., Iwase, H., Sasagawa, M., Nakamura, T., Tokuyama, O., Takano, M., Sugiyama, T., Sawasaki, T., Isonishi, S., Takehara, K., Nakai, H., Okamoto, A., Mandai, M., & Konishi, I. (2019). The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology

Group. *Gynecologic Oncology*, 153(2), 312–319.

<https://doi.org/10.1016/j.ygyno.2019.02.010>

Nair, V., & Sughija, G. (2020). Histopathological study of ovarian tumors in a tertiary care center. *Obsgyne Review: Journal of Obstetric and Gynecology*, 6(1), 22–27. <https://doi.org/10.17511/joog.2020.i01.04>

Nakayama, K., Razia, S., Ishibashi, T., & Kyo, S. (2024). Current concept of low-grade serous ovarian carcinoma. *Translational Cancer Research*, 13(1), 6–10. <https://doi.org/10.21037/tcr-23-1161>

Natoli, M., Bonito, N., Robinson, J. D., Ghaem-Maghami, S., & Mao, Y. (2020). Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade. *Cancer Immunology, Immunotherapy*, 69(8), 1391–1401. <https://doi.org/10.1007/s00262-020-02544-5>

Ng, J. K. M., Chow, L. H., Ngai, A. M. Y., Chan, R. C. K., Lee, J. H. S., Lee, A. L. H., Li, J. J. X., To, C. C. K., & Tse, G. M. (2023). Number Needed to Diagnose in Malignant Ascites: Effects of Volume, Repeating Collection, and Primary Malignancy on Diagnostic Performance in Peritoneal Fluid Cytology. *Acta Cytologica*, 67(4), 434–443. <https://doi.org/10.1159/000529855>

Okunade, K. S., Adejimi, A. A., Ohazurike, E. O., Salako, O., Osunwusi, B., Adenekan, M. A., Ugwu, A. O., Soibi-Harry, A., Dawodu, O., Okunowo, A. A., Anorlu, R. I., & Berek, J. S. (2021). Predictors of Survival Outcomes after Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria. *Journal of Global Oncology*, 7, 89–98. <https://doi.org/10.1200/GO.20.00450>

Oliveira, D. V. N. P., Prahm, K. P., Christensen, I. J., Hansen, A., Høgdall, C. K., & Høgdall, E. V. (2021). Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. *Scientific Reports*, 11(1), 5438. <https://doi.org/10.1038/s41598-021-84953-9>

Orlova, R., Malkova, A., Zhukova, N. V, Kaledina, E., & Demchenkova, A. (2022). Poster Session NGS analysis of germline mutation profile of patients with hepatocellular carcinoma in. *Journal of Clinical Oncology*, 20, 10585.

<https://doi.org/10.1200/JCO.2022.40.16>

- Pan, Q., Wei, M., Lu, M., Xu, Y., Xie, X., & Li, X. (2023). The Role of Perioperative C-Reactive Protein in Predicting the Prognosis of Epithelial Ovarian Carcinoma. *Cancer Management and Research*, 15(November 2022), 233–243. <https://doi.org/10.2147/CMAR.S385974>
- Patton, R., Paval, D. R., McDonald, J. J., Brown, D., Gallagher, I. J., Skipworth, R. J. E., McMillan, D. C., Dolan, R. D., Fallon, M., & Laird, B. J. A. (2021). Relationship between cytokines and symptoms in people with incurable cancer: A systematic review. In *Critical Reviews in Oncology/Hematology* (Vol. 159, Issue July 2020, p. 103222). Elsevier B.V. <https://doi.org/10.1016/j.critrevonc.2021.103222>
- Paulus, A., Cicenas, S., Zvirbule, Ž., Paz-Ares, L. G., Awada, A., García-Ribas, I., Losic, N., & Žemaitis, M. (2022). Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. <https://api.semanticscholar.org/CorpusID:249453276>
- Penet, M. F., Krishnamachary, B., Wildes, F. B., Mironchik, Y., Hung, C. F., Wu, T. C., & Bhujwalla, Z. M. (2018). Ascites volumes and the ovarian cancer microenvironment. *Frontiers in Oncology*, 8(DEC), 1–8. <https://doi.org/10.3389/fonc.2018.00595>
- Peres, L. C., Mallen, A. R., Townsend, M. K., Poole, E. M., Trabert, B., Allen, N. E., Arslan, A. A., Dossus, L., Fortner, R. T., Gram, I. T., Hartge, P., Idahl, A., Kaaks, R., Kvaskoff, M., Magliocco, A. M., Merritt, M. A., Quiros, R. J., Tjonneland, A., Trichopoulou, A., ... Tworoger, S. S. (2019). High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the ovarian cancer Cohort Consortium. *Cancer Research*, 79(20), 5442–5451. <https://doi.org/10.1158/0008-5472.CAN-19-1554>
- Piatek, S., Panek, G., Lewandowski, Z., Bidzinski, M., Piatek, D., Kosinski, P., & Wielgos, M. (2020). Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer. *Journal of*

- Ovarian Research*, 13(1), 1–10. <https://doi.org/10.1186/s13048-020-00681-0>
- Prat, J., Belhadj, H., Berek, J., Bermudez, A., Bhatla, N., Cain, J., Denny, L., Fujiwara, K., Hacker, N., Åvall-Lundqvist, E., Mutch, D., Odicino, F., Pecorelli, S., Prat, J., Quinn, M., Seoud, M. A. F., & Shrivastava, S. K. (2015). Figo's staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication. *Journal of Gynecologic Oncology*, 26(2), 87–89. <https://doi.org/10.3802/jgo.2015.26.2.87>
- Purbadi, S., Anggraeni, T. D., & Vitria, A. (2021). Early stage epithelial ovarian cancer metastasis through peritoneal fluid circulation. *Journal of Ovarian Research*, 14(1), 1–5. <https://doi.org/10.1186/s13048-021-00795-z>
- Quiralte, M., Barquin, A., Yagüe, M., Navarro, P., Sevillano, E., Rodriguez-Moreno, J. F., Balarezo, A., Peinado, H., Izquierdo, E., Millan, C., Lopez, I., Ruiz-Llorente, S., & García-Donas, J. (2023). Proteomic profiling of peritoneal fluid-derived exosomes as a tool for the identification of prognostic markers in advanced ovarian carcinomas. *Journal of Clinical Oncology*, 41(16_suppl), e17561–e17561. https://doi.org/10.1200/jco.2023.41.16_suppl.e17561
- Radu, M. R., Prădatu, A., Duică, F., Micu, R., Crețoiu, S. M., Suciu, N., Crețoiu, D., Varlas, V. N., & Rădoi, V. E. (2021). Ovarian cancer: Biomarkers and targeted therapy. *Biomedicines*, 9(6), 1–21. <https://doi.org/10.3390/biomedicines9060693>
- Rambau, P. F., Köbel, M., Tilley, D., Mremi, A., Lukande, R., & Muller, W. (2020). Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America. *Diagnostic Pathology*, 15(1), 1–11. <https://doi.org/10.1186/s13000-020-01000-3>
- Rébé, C., & Ghiringhelli, F. (2020). Interleukin-1 β and Cancer. *Cancers*.
- Rousing, I. G., Kallestrup, P., Baun, M. L. L., & Virgilsen, L. F. (2022). Characteristics of ovarian cancer patients with first presentation in general practice. *Danish Medical Journal*, 69(4), 1–9.
- Sarkar, S., Saha, S. A., Sarkar, P., Banerjee, S., & Mitra, P. (2023). The molecular prognostic score, a classifier for risk stratification of high-grade serous

ovarian cancer. *BioRxiv*.

<https://www.embase.com/search/results?subaction=viewrecord&id=L2025674972&from=export%0Ahttp://dx.doi.org/10.1101/2023.06.19.545525>

Schauer, I. G., Zhang, J., Xing, Z., Guo, X., Mercado-Urbe, I., Sood, A. K., Huang, P., & Liu, J. (2013). Interleukin-1 β promotes ovarian tumorigenesis through a p53/NF- κ B-mediated inflammatory response in stromal fibroblasts. *Neoplasia (United States)*, 15(4), 409–420.
<https://doi.org/10.1593/neo.121228>

Sekine, M., Asano, T., & Mashima, H. (2022). The Diagnosis of Small Gastrointestinal Subepithelial Lesions by Endoscopic Ultrasound-Guided Fine Needle Aspiration and Biopsy. *Diagnostics*, 12(4).
<https://doi.org/10.3390/diagnostics12040810>

Shi, Y., Dai, M., Zhang, Y., Qi, Y., Li, Z., & Cai, H. (2021). Residual tumor diameter predicts progression after primary debulking surgery of ovarian clear cell carcinoma (Occc): Clinicopathologic study of stage ii-iv occc patients from a single institution. *Cancer Management and Research*, 13, 2215–2222. <https://doi.org/10.2147/CMAR.S293677>

Shih, I. M., Wang, Y., & Wang, T. L. (2021). The Origin of Ovarian Cancer Species and Precancerous Landscape. In *American Journal of Pathology* (Vol. 191, Issue 1, pp. 26–39). American Society for Investigative Pathology.
<https://doi.org/10.1016/j.ajpath.2020.09.006>

Shimura, T., Shibata, M., Gonda, K., Murakami, Y., Noda, M., Tachibana, K., Abe, N., & Ohtake, T. (2019). Prognostic impact of interleukin-6 and c-reactive protein on patients with breast cancer. *Oncology Letters*, 17(6), 5139–5146. <https://doi.org/10.3892/ol.2019.10183>

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, 70(1), 7–30.
<https://doi.org/10.3322/caac.21590>

Sigmon, D., & Fatima, S. (2022). Fine needle aspiration. In *Cancer Investigation* (Vol. 22, Issue 4, pp. 620–628). <https://doi.org/10.1081/CNV-200027160>

Singh, N. (2023). TNM/FIGO Classification, Pathology of the Ovary BT -

Gynecologic Pathology. In S. Stolnicu & R. Ali-Fehmi (Eds.), *Gynecologic Pathology* (pp. 591–594). Springer International Publishing.

https://doi.org/10.1007/978-3-030-97378-0_5652

Singh, N., Benson, J. L., Gan, C., Anglesio, M., Arora, R., Faruqi, A. Z. F., Hirschowitz, L., Kommoss, F., Scott, K., Trevisan, G., Leen, S. L. S., Wilkinson, N., Gilks, C. B., & McCluggage, W. G. (2018). Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. *International Journal of Gynecological Pathology*, 37(4), 324–330.

<https://doi.org/10.1097/PGP.0000000000000429>

Sköld, C., Koliadi, A., Enblad, G., Stålberg, K., & Glimelius, I. (2021). Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes. *International Journal of Cancer*, 150(5), 773–781.

<https://doi.org/10.1002/ijc.33844>

Socha, M. W., Malinowski, B., Puk, O., Wartęga, M., Bernard, P., Nowaczyk, M., Wolski, B., & Wiciński, M. (2021). C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. *Critical Reviews in Oncology/Hematology*, 164(July).

<https://doi.org/10.1016/j.critrevonc.2021.103419>

Stewart, C., Ralyea, C., & Lockwood, S. (2019). Ovarian Cancer: An Integrated Review. In *Seminars in Oncology Nursing* (Vol. 35, Issue 2, pp. 151–156). Elsevier Inc. <https://doi.org/10.1016/j.soncn.2019.02.001>

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249.

<https://doi.org/10.3322/caac.21660>

Szender, J. B., Emmons, T., Belliotti, S., Dickson, D., Khan, A., Morrell, K., Khan, A. N. M. N., Singel, K. L., Mayor, P. C., Moysich, K. B., Odunsi, K., Segal, B. H., & Eng, K. H. (2017). Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. *Gynecologic Oncology*, 146(3),

491–497. <https://doi.org/10.1016/j.ygyno.2017.06.008>

Tian, B. Q., Wang, S. W., Xu, J. Y., Wu, S. G., & Zhou, J. (2024). Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015.

Frontiers in Oncology, 14(March), 1–14.

<https://doi.org/10.3389/fonc.2024.1360663>

Tjokrowidjaja, A., Lee, C. K., Friedlander, M., Gebiski, V., Gladieff, L., Ledermann, J., Penson, R., Oza, A., Korach, J., Huzarski, T., Manso, L., Pisano, C., Asher, R., Lord, S. J., Kim, S. I., Lee, J. Y., Colombo, N., Park-Simon, T. W., Fujiwara, K., ... Pujade-Lauraine, E. (2020). Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.

European Journal of Cancer, 139, 59–67.

<https://doi.org/10.1016/j.ejca.2020.08.021>

Toufakis, V., Katuwal, S., Pukkala, E., & Tapanainen, J. S. (2021). Impact of parity on the incidence of ovarian cancer subtypes: a population-based case–control study. *Acta Oncologica*, 60(7), 850–855.

<https://doi.org/10.1080/0284186X.2021.1919754>

Van Cutsem, E., Collignon, J., Eefsen, R., Ochsenreither, S., Zvirbule, Z., Ivanauskas, A., Millrud, C. R., Skoog, P., Losic, N., Magnusson, S., Sanfridson, A., & Liberg, D. (2023). Abstract 2172: Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel. *Cancer Research*, 83(7_Supplement), 2172. <https://doi.org/10.1158/1538-7445.AM2023-2172>

Varma, M., Collins, L. C., Chetty, R., Karamchandani, D. M., Talia, K., Dormer, J., Vyas, M., Conn, B., Guzmán-Arocho, Y. D., Jones, A. V., Pring, M., & McCluggage, W. G. (2023). Macroscopic examination of pathology specimens: a critical reappraisal. *Journal of Clinical Pathology*, 164–168.

<https://doi.org/10.1136/jcp-2023-209045>

Vergote, I., Gonzalez-Martin, A., Lorusso, D., Gourley, C., Mirza, M. R., Kurtz,

- J. E., Okamoto, A., Moore, K., Kridelka, F., McNeish, I. and, & Reuss, A. (2022). Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. *The Lancet Oncology* 23, No. 8 (2022): E374-E384.
- Vergote, Ignace, Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., McCluggage, W. G., Perren, T., Panici, P. B., Kenter, G., Casado, A., Mendiola, C., Stuart, G., Reed, N. S., Kehoe, S., ... Petru, E. (2018). Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. *The Lancet Oncology*, 19(12), 1680–1687. [https://doi.org/10.1016/S1470-2045\(18\)30566-7](https://doi.org/10.1016/S1470-2045(18)30566-7)
- Wandira, N. A., Dinengsih, S., & Novelia, S. (2023). Analysis of Ovary Cancer in the Gynecology Room. *Jurnal Midpro*, 15(1), 166–179. <https://doi.org/10.30736/md.v15i1.506>
- Wang, Q., Feng, X., Liu, X., & Zhu, S. (2022). Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis. *Frontiers in Oncology*, 12(April), 1–10. <https://doi.org/10.3389/fonc.2022.868061>
- Wang, Qiao, Zheng, Y., Wang, P., Zhang, J., Liu, H., Li, Q., Yin, R., Bian, C., Peng, H., & Peng, Z. (2021). The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study. *Journal of Ovarian Research*, 14(1), 1–7. <https://doi.org/10.1186/s13048-021-00908-8>
- Wang, Y., Zhang, Z., Wang, J., & Zhang, X. (2020). Association between C-reactive protein level and subsequent risk of ovarian cancer: A meta-analysis of 13 cohorts in 1,852 ovarian cancer patients. *Medicine (United States)*, 99(5), E18821. <https://doi.org/10.1097/MD.00000000000018821>
- Watanabe, T., Hashimoto, T., Sugino, T., Soeda, S., Nishiyama, H., Morimura, Y., Yamada, H., Goodison, S., & Fujimori, K. (2012). Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression

facilitating peritoneal dissemination. *Journal of Ovarian Research*, 5(1), 7.

<https://doi.org/10.1186/1757-2215-5-7>

Wertel, I., Suszczyk, D., Pawłowska, A., Biliska, M., Chudzik, A., Skiba, W., Paduch, R., & Kotarski, J. (2020). Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+Inflammatory Cells with PD-L1+/PD-L2+Expression in Patients with Different Manifestation of Ovarian Cancer.

Journal of Immunology Research, 2020.

<https://doi.org/10.1155/2020/1715064>

Xu, J. F., Cen, Y. X., Tang, S. S., Ren, Y., & Lyu, W. G. (2022). [IL-1 β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells]. *Zhonghua fu chan ke za zhi*, 57(7), 519–529.

<https://doi.org/10.3760/cma.j.cn112141-20220509-00307>

Xu, X., Deng, F., Lv, M., Ren, B., Guo, W., & Chen, X. (2016). Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. *Journal of Ovarian Research*, 9(1), 1–8. <https://doi.org/10.1186/s13048-016-0294-z>

Yamagami, W., Nagase, S., Takahashi, F., Ino, K., Hachisuga, T., Mikami, M., Enomoto, T., Katabuchi, H., & Aoki, D. (2020). A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of japan society of obstetrics and gynecology (Jsog): Disparity between serous carcinoma and cl. *Journal of Gynecologic Oncology*, 31(4), 1–10.

<https://doi.org/10.3802/jgo.2020.31.e45>

Yang, D., Li, H., Sun, X., Yang, S., Wang, K., & Liu, Z. (2020). Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer. *Scientific Reports*, 10(1), 1–7.

<https://doi.org/10.1038/s41598-020-77167-y>

Yang, Y., Li, X., Qian, H., Di, G., Zhou, R., Dong, Y., Chen, W., & Ren, Q. (2022). C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis. *Computational Intelligence and Neuroscience*.

<https://doi.org/10.1155/2022/6833078>

- Yang, Yingying, Li, X., Qian, H., Di, G., Zhou, R., Dong, Y., Chen, W., & Ren, Q. (2022). *C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis*. 2022.
- Yu, K. H., Hu, V., Wang, F., Matulonis, U. A., Mutter, G. L., Golden, J. A., & Kohane, I. S. (2020). Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. *BMC Medicine*, 18(1), 1–14. <https://doi.org/10.1186/s12916-020-01684-w>
- Zhang, H., & Lu, B. (2020). microRNAs as biomarkers of ovarian cancer. *Expert Review of Anticancer Therapy*, 0(0), 1. <https://doi.org/10.1080/14737140.2020.1760095>
- Zhang, W., Zhang, Z., & Qian, L. (2024). Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis. *World Journal of Surgical Oncology*, 22(1), 1–12. <https://doi.org/10.1186/s12957-023-03290-5>
- Zheng, L., Cui, C., Shi, O., Lu, X., Li, Y. kun, Wang, W., Li, Y., & Wang, Q. (2020). Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017. *Gynecologic Oncology*, 159(1), 239–247. <https://doi.org/10.1016/j.ygyno.2020.07.008>
- Zhou, Z., Wang, X., Ren, X., Zhou, L., Wang, N., & Kang, H. (2021). Disease Burden and Attributable Risk Factors of Ovarian Cancer From 1990 to 2017: Findings From the Global Burden of Disease Study 2017. *Frontiers in Public Health*, 9(September). <https://doi.org/10.3389/fpubh.2021.619581>